Log in to search using one of your social media accounts:

 

Extralymphatic Disease Is An Independent Prognostic Factor In Hodgkin ’s Lymphomas

This study aims to identify the characteristics and outcomes of patients with extralymphatic HL. We performed a retrospective single institution study of 341 cases (207 (61%) males and 134 (39%) females) with a median follow-up of 44 months; 55 patients (16%) had extralymphatic disease. The sites were the lung in 29 patients (44%), bone in 22 (33%), liver in 5 (18%) and kidney in 3 (5%). In 46 patients (86%) only one organ was involved, while in 7 patients (13%) extralymphatic disease was present in 2 sites and in 2 patients (3%) in 3 sites. The extralymphatic disease group had a poorer prognosis than the lymphatic group. Complete remission (CR) rates in the extralymphatic and lymphatic patient subsets were 56% vs 71% (p=0.003), respectively. In our study, extralymphatic disease in pts with HL was a rare occurrence (16%) associated with a poor clinical outcome.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Steven M. Bair, Anthony Mato, Jakub Svoboda Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and chec...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages > 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at the ages over 50. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes one percent of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as Dexamethasone (DEX) and Bortezomib (BTZ), it is still an incurable malignancy due to ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages> 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development of drug resistance. The tumor cells develop resistance to apoptosis, resulting in greater cell survival, and, ultimately, develop drug resistance by changing the various signaling pathways involved in cell proliferation, survival, differ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
Conclusion A PET-guided strategy with early salvage therapy and high-dose therapy/autologous stem cell transplantation for patients with interim PET–2-positive findings is safe and feasible and provide similar outcome as patients with a negative PET-2. Micro-Abstract Hodgkin lymphoma is a curable disease with outcomes depending on initial prognostic factors and interim treatment response. Here, we conducted a phase II trial in advanced stage Hodgkin lymphoma to assess the feasibility and efficacy of a positron emission tomography-adapted strategy with early salvage for poor metabolic responders. We show that this str...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Low-dose RT, administered to all sites of original involvement, was associated with improved PFS, even in the setting of a metabolic CR after ABVD. Micro-Abstract The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Primary cutaneous lymphomas are a heterogeneous group of extranodal non-Hodgkin lymphomas, approximately 25% of which are B-cell derived, which have are classified into 3 major entities since 2005: primary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), and primary cutaneous marginal zone lymphoma (PCMZL).1,2 In 2016, a very rare entity, intravascular lymphoma, was introduced and predominantly involves the skin.3 The diagnosis and classification of primary cutaneous B-cell lymphoma (PCBCL) requires an excisional or punch biopsy for careful morphologic and ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Ever since I began doing research on myeloma, one of my certainties–although with something like myeloma you can never be absolutely certain!!!–has been that myeloma is NOT a hereditary disease. Yes, of course, I’ve read about a few patients who had relatives with myeloma, but…only a few. If you do an online search, you will find that not much is known about the causes of myeloma. A few known ones are things such as pesticide exposure, past exposure to radiation, genetic changes that turn our plasma cells into MM cells…stuff like that. The family connection seems to be a minor one… To...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll inherited cancer myeloma Source Type: blogs
The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematolo...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
More News: Cancer & Oncology | Hodgkin's Disease | Leukemia | Liver | Lymphoma | Myeloma | Study | Urology & Nephrology